1. Home
  2. SBLX vs ARTL Comparison

SBLX vs ARTL Comparison

Compare SBLX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBLX

StableX Technologies Inc.

HOLD

Current Price

$2.35

Market Cap

3.6M

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.32

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBLX
ARTL
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBLX
ARTL
Price
$2.35
$1.32
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
102.8K
28.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.25
$0.85
52 Week High
$7.85
$28.60

Technical Indicators

Market Signals
Indicator
SBLX
ARTL
Relative Strength Index (RSI) 38.59 47.81
Support Level $2.25 $1.10
Resistance Level $2.82 $1.52
Average True Range (ATR) 0.26 0.14
MACD -0.00 -0.01
Stochastic Oscillator 23.92 51.62

Price Performance

Historical Comparison
SBLX
ARTL

About SBLX StableX Technologies Inc.

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: